General information on the coronavirus pandemic
SARS-CoV-2, the in December 2019 newly identified coronavirus strain, has already infected 133,146,550 people worldwide (confirmed cases as of 09 April 2021, WHO). The corona virus disease 2019 (COVID-19) caused by SARS-CoV-2 infections imposes a major threat for the world’s health care systems and is leading to thousands of deaths. As of 09 April 2021, already 2,888,530 confirmed SARS-CoV-2 infected patients died (WHO). The virus binds to and invades the alveolar lung cells through the angiotensin converting enzyme 2 (ACE2). Most common symptoms are fever and dry cough. Most patients have mild cold symptoms, the rather severe cases suffer from dyspnea, low blood oxygen saturation and lung infiltrates. The critical patients (around 5%) experience respiratory failure, and/or multiple organ dysfunction or failure. ACE2 is not only expressed on lung cells but also in the heart and vascular endothelium and COVID-19 is linked to increased morbidity and mortality from cardiovascular disease.
Current publications on COVID-19 from CPI members
Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry
SARS-CoV-2 infection is associated with adverse outcomes in patients with cardiovascular disease. Here, we analyzed whether specific biomarkers predict the clinical course of COVID-19 in patients with cardiovascular comorbidities.
Methods and results
We enrolled 2147 patients with SARS-CoV-2 infection which were included in the Lean European Open Survey on SARS-CoV‑2 (LEOSS)-registry from March to June 2020. Clinical data and laboratory values were collected and compared between patients with and without cardiovascular comorbidities in different clinical stages of the disease. Predictors for mortality were calculated using multivariate regression analysis. We show that patients with cardiovascular comorbidities display significantly higher markers of myocardial injury and thrombo-inflammatory activation already in the uncomplicated phase of COVID-19. In multivariate analysis, elevated levels of troponin [OR 1.54; (95% CI 1.22–1.96), p < 0.001)], IL-6 [OR 1.69 (95% CI 1.26–2.27), p < 0.013)], and CRP [OR 1.32; (95% CI 1.1–1.58), p < 0.003)] were predictors of mortality in patients with COVID-19.
Patients with cardiovascular comorbidities show elevated markers of thrombo-inflammatory activation and myocardial injury, which predict mortality, already in the uncomplicated phase of COVID-19. Starting targeted anti-inflammatory therapy and aggressive anticoagulation already in the uncomplicated phase of the disease might improve outcomes after SARS-CoV-2 infection in patients with cardiovascular comorbidities.
Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry
Immunoglobulin Deficiency as an Indicator of Disease Severity in Patients with COVID-19
find original publication here
Despite the pandemic status of COVID-19, there is limited information about host risk factors and treatment beyond supportive care. Immunoglobulin G (IgG) could be a potential treatment target. Our aim was to determine the incidence of IgG deficiency and associated risk factors in a cohort of 62 critical ill COVID-19 patients admitted to two German ICUs (72.6% male, median age: 61 years). 13 (21.0%) of the patients displayed IgG deficiency (IgG <7 g/L) at baseline (predominant for the IgG1, IgG2, and IgG4 subclasses). IgG-deficient patients had worse measures of clinical disease severity than those with normal IgG levels (shorter duration from disease onset to ICU admission, lower ratio of PaO2 to FiO2, higher Sequential Organ Failure Assessment score, and higher levels of ferritin, neutrophil-to-lymphocyte ratio and serum creatinine). IgG-deficient patients were also more likely to have sustained lower levels of lymphocyte counts and higher levels of ferritin throughout the hospital stay. Furthermore, IgG-deficient patients compared to those with normal IgG levels displayed higher rates of acute kidney injury (76.9% vs. 26.5%; p=0.005) and death (46.2% vs. 14.3%; p=0.012), longer ICU (28 [6-48] vs. 12 [3-18] days; p=0.012) and hospital length of stay (30 [22-50] vs. 18 [9-24] days; p=0.004). Multivariable logistic regression showed increasing odds of 90-day overall mortality associated with IgG-deficiency (OR 12.8, 95% CI 1.5-108.4; p=0.019). IgG deficiency might be common in critically ill COVID-19 patients, and warrants investigation as both a marker of disease severity as well as a potential therapeutic target.
Keywords: Cytokine release syndrome; Immunodysregulation; Respiratory failure; Severe acute respiratory syndrome coronavirus 2.
Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)
Question What are the cardiovascular effects in unselected patients with recent coronavirus disease 2019 (COVID-19)?
Findings In this cohort study including 100 patients recently recovered from COVID-19 identified from a COVID-19 test center, cardiac magnetic resonance imaging revealed cardiac involvement in 78 patients (78%) and ongoing myocardial inflammation in 60 patients (60%), which was independent of preexisting conditions, severity and overall course of the acute illness, and the time from the original diagnosis.
Meaning These findings indicate the need for ongoing investigation of the long-term cardiovascular consequences of COVID-19.
Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation.
|Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation.|
|Böhm M, Frey N, Giannitsis E, Sliwa K, Zeiher AM.|
|Clin Res Cardiol. 2020 May 27. doi: 10.1007/s00392-020-01656-3. [Epub ahead of print] Review.|
Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. EHJ
ACE2 is a protein on the surface of cells and serves as the entry gate for the SARS-CoV-2 coronavirus. A Frankfurt research group was able to show that ACE2 is significantly increased in tissue samples from patients with cardiovascular diseases.
COVID-19 disease causes severe lung damage with thousands of deaths. It is already known that the SARS-CoV-2 virus attacks lung cells that present a specific protein on their surface, the so-called ACE2 receptor. So far, mainly the effects of COVID-19 on lung health have been reported. However, patients with cardiovascular diseases are affected by a considerably more severe course of the disease. You have a multiple increase in mortality from COVID-19 disease. There is currently a lot of discussion about which cells contain ACE2 and whether so-called angiotensin converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARB) are used to enhance the presentation of the SARS-CoV-2 receptor ACE2 in the lungs and lead heart cells. Both are drugs that are often used to treat cardiovascular diseases.
An interdisciplinary cardiac research team at the University Hospital Frankfurt led by Prof. Stefanie Dimmeler, director of the Institute for Cardiovascular Regeneration, Prof. Andreas Zeiher, director of cardiology, and Prof. Thomas Walther, director of the Cardiac surgery, showed in a publication in the European Heart Journal the differences of the ACE2 presentation on tissue samples from patients with cardiovascular diseases. The researchers discovered that ACE2, especially in cardiac muscle cells and in the vascular cells of the heart of patients with heart disease, was significantly increased compared to healthy control groups. Interestingly, the investigations were also able to demonstrate for the first time that cardiac cells from patients treated with ACE inhibitors had a significantly higher ACE2 presentation.
These data suggest that it is not only important to monitor SARS-CoV-2 infected for cardiovascular complications, but in particular to further investigate the influence of ACE2 inhibitors and ARB blockers on the course of disease of COVID-19.
original publication: Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. Luka Nicin et.al. European Heart Journal, ehaa311, https://doi.org/10.1093/eurheartj/ehaa311
Quelle: Pressemitteilung Universitätsklinikum Frankfurt
Severe organising pneumonia following COVID-19
Vadász I, Husain-Syed F, Dorfmüller P, Roller FC, Tello K, Hecker M, Morty RE, Gattenlöhner S, Walmrath HD, Grimminger F, Herold S Seeger W
Various forms of diffuse parenchymal lung disease have been proposed as potential consequences of severe COVID‑19. We describe the clinical, radiological and histological findings of patients with COVID‑19-associated acute respiratory distress syndrome who later developed severe organising pneumonia including longitudinal follow-up. Our findings may have important implications for the therapeutic modalities in the late-phase of severe COVID‑19 and might partially explain why a subgroup of COVID‑19 patients benefits from systemic corticosteroids.
Keywords: ARDS; bronchoscopy; critical care; rare lung diseases; viral infection.
Impact of the COVID-19 pandemic on cardiovascular mortality and catherization activity during the lockdown in central Germany: an observational study
Nef HM, Elsässer A, Möllmann H, Abdel-Hadi M, Bauer T, Brück M, Eggebrecht H, Ehrlich JR, Ferrari MW, Fichtlscherer S, Hink U, Hölschermann H, Kacapor R, Koeth O, Korboukov S, Lamparter S, Laspoulas AJ, Lehmann R, Liebetrau C, Plücker T, Pons-Kühnemann J, Schächinger V, Schieffer B, Schott P, Schulze M, Teupe C, Vasa-Nicotera M, Weber M, Weinbrenner C, Werner G, Hamm CW,Dörr O
During the COVID-19 pandemic, hospital admissions for cardiac care have declined. However, effects on mortality are unclear. Thus, we sought to evaluate the impact of the lockdown period in central Germany on overall and cardiovascular deaths. Simultaneously we looked at catheterization activities in the same region.
Methods and results
Data from 22 of 24 public health-authorities in central Germany were aggregated during the pandemic related lockdown period and compared to the same time period in 2019. Information on the total number of deaths and causes of death, including cardiovascular mortality, were collected. Additionally, we compared rates of hospitalization (n = 5178) for chronic coronary syndrome (CCS), acute coronary syndrome (ACS), and out of hospital cardiac arrest (OHCA) in 26 hospitals in this area. Data on 5,984 deaths occurring between March 23, 2020 and April 26, 2020 were evaluated. In comparison to the reference non-pandemic period in 2019 (deaths: n = 5832), there was a non-significant increase in all-cause mortality of 2.6% [incidence rate ratio (IRR) 1.03, 95% confidence interval (CI) 0.99–1.06; p = 0.16]. Cardiovascular and cardiac mortality increased significantly by 7.6% (IRR 1.08, 95%-CI 1.01–1.14; p = 0.02) and by 11.8% (IRR 1.12, 95%-CI 1.05–1.19; p < 0.001), respectively. During the same period, our data revealed a drop in cardiac catherization procedures.
During the COVID-19-related lockdown a significant increase in cardiovascular mortality was observed in central Germany, whereas catherization activities were reduced. The mechanisms underlying both of these observations should be investigated further in order to better understand the effects of a pandemic-related lockdown and social-distancing restrictions on cardiovascular care and mortality.
COVID-19 myocarditis and prospective heart failure burden
Introduction: COVID-19 is causing considerable morbidity and mortality worldwide. Serious respiratory complications aside, the heart is also frequently involved. The mechanisms and the extent of the myocardial injury, along with the short and long-term cardiovascular (CV) outcomes in COVID-19 survivors remain unclear. Areas covered: myocardial injury has been found in a considerable proportion of hospitalized COVID-19 patients and is associated with a worse prognosis. The late onset of CV complications with myocarditis-like changes revealed by CMR has been reported in COVID-19 survivors. Previous observational studies on viral myocarditis provide evidence of a significant incomplete recovery with residual dysfunction and remodeling of left ventricle. Incomplete recovery is thought to be the result of persistent myocardial inflammation due to a post-viral autoimmune response. Considering the significant inflammatory nature of COVID-19, COVID-19 survivors may be at risk of developing persistent residual myocardial injury, the sequelae of which are unclear. Expert commentary: COVID-19 is an emerging threat for the heart. The extent of CV injury, along with the short and long-term sequelae, requires further investigation. The early detection of residual myocardial changes in COVID-19 survivors is of utmost importance in order to identify those patients at risk of CV complication development.
Keywords: COVID-19; cardiac magnetic resonance; heart failure; myocarditis.
SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes
Aprotinin Inhibits SARS-CoV-2 Replication
Bojkova D, Bechtel M, Mclaughlin KM, Mcgreig JE, Klann K, Bellinghausen C, Rohde G, Jonigk D, Braubach P, Ciesek S, Münch C, Wass MN, Michaelis M Cinatl J, Jr.
Severe acute respiratory syndrome virus 2 (SARS-CoV-2) is the cause of the current coronavirus disease 19 (COVID-19) pandemic. Protease inhibitors are under consideration as virus entry inhibitors that prevent the cleavage of the coronavirus spike (S) protein by cellular proteases. Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations. An analysis of proteomics and translatome data indicated that SARS-CoV-2 replication is associated with a downregulation of host cell protease inhibitors. Hence, aprotinin may compensate for downregulated host cell proteases during later virus replication cycles. Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air–liquid interface cultures) and against four virus isolates. In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity. An approved aprotinin aerosol may have potential for the early local control of SARS-CoV-2 replication and the prevention of COVID-19 progression to a severe, systemic disease.
Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.
Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.
Bojkova D, Klann K, Koch B, Widera M, Krause D, Ciesek S, Cinatl J, Münch C.
Nature. 2020 May 14. doi: 10.1038/s41586-020-2332-7.
Single-Cell Transcriptomics Data Survey Reveals SARS-CoV-2 Entry Factors Highly Expressed in Nasal Epithelial Cells Together with Innate Immune Genes
In this study, we have investigated which cells in the body can be infected by the covid-19 virus (SARS-CoV-2). We use data from a large-scale international project that aims to map all cells in the body according to their gene expression profiles (Human Cell Atlas Project).
It is known from previous studies that the covid-19 virus can only infect cells that express two genes necessary for viral entry into human cells (ACE2 and TMPRSS). By examining their expression levels in thousands of cells from human tissues, we discovered that ACE2, along with TMPRSS, is expressed in epithelial cells of the respiratory system, cornea and intestine which may explain the extensive spread of the covid-19 virus. These genes are expressed primarily in the nasal cells along with other genes that are part of our innate immune system. This highlights the potential role of nasal cells in early infection and in counteracting infection. The expression of ACE2 together with TMPRSS2 in other barrier tissues points to the need to investigate alternative transmission pathways. For example, the expression of the genes in the esophagus and colon could explain why the virus has been found in the stools of COVID-19 patients, indicating a potential fecal-oral transmission. Expression of the genes in superficial epithelial cells in the eye may explain symptoms in the eye that can be observed in a small proportion of COVID-19 patients. These discoveries have implications for our strategies to protect us and to treat infected individuals. For example, given the likely role of the nasal cells, drugs administered intranasally may be very effective in limiting both infection and spread.
original publication: Single-Cell Transcriptomics Data Survey Reveals SARS-CoV-2 Entry Factors Highly Expressed in Nasal Epithelial Cells Together with Innate Immune Genes. Waradon Sungnak et al., Nat Med (2020). https://doi.org/10.1038/s41591-020-0868-6
Quelle: Summary by Christos Samakovlis
The CPI is working with great effort on understanding COVID-19 pathology and the development of potential treatment options.
We are currently investigating the following major questions:
How can lung injury induced by SARS-CoV-2 be prevented?
There are immense activities world-wide to identify novel therapeutic options for treating COVID-19. Based on previous studies of CPI researchers demonstrating that inhaled GM-CSF prevents lung failure of acute pneumonia (Cakarova et al, AJRCCM, 2009; Unkel et al, JCI, 2012), and a multicenter phase II trial is currently testing this therapeutic strategy in pneumonia-realted ARDS including COVID patients. This approach might be also suitable to prevent detrimental development of COVID-19-ARDS from early stages of pneumonia. Depending on the availability of substance, a clinical trial is planned.
In addition, cell therapies showing that immunosuppressive mesenchymal stromal cells protect bronchopulmonary stem cells destruction caused by virus infection were shown to prevent detrimental courses of the disease (Salzig et al, EMBOJ, 2019). In collaboration with the LOEWE Center for Cell- and Gene Therapy, highly efficient, off the shelf available immune suppressive MSCs were developed, which might be usable also as therapeutics for COVID-19.
Does SARS-CoV-2 directly affect the vasculature and the heart?
The putative receptor for SARS-CoV-2 ACE2 is not only expressed on lung cells but also in the heart and vascular endothelium (Wevers and Hoek, Futur Med, 2010). Moreover, patients with underlying cardiovascular disease represent a significant proportion of patients, who may suffer from severe courses after COVID-19 infections (Zhou et al, The Lancet,2020; Wang et al., JAMA, 2020; Zheng, Nat Rev. Cardiol., 2020). Therefore, the CPI is addressing the impact of COVID-19 on the cardiovascular system. First data suggest that particularly pericytes and cardiomyocyte showed highest expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. Therefore, CPI researchers now test whether SARS-CoV-2 can directly affect cells of the cardiovascular system by assessing the effect of SARS-CoV-2 isolates on primary human cells in collaboration with Prof. Ciesek (Frankfurt).
Could ACE-inhibitor treatment be detrimental in COVID-19 patients?
First studies show that ACE-inhibitor treatment, which is often used to treat patients with cardiovascular diseases, augments the expression of the SARS-CoV-2 receptor ACE2 in lung cells. This is supposed to be mediated by an effect on angiotensin II, which is known to reduce ACE2 expression. Thus, ACE inhibition decreases angiotensin II, leading to an indirect up-regulation of ACE2 (Wevers and Hoek, Futur Med, 2010). To test whether this indeed is relevant in the context of COVID-19, CPI researchers are currently determining the regulation of ACE2 in patients, which were treated with ACE2 inhibitors. In addition, ex vivo lung explants (precision-cut lung slices, PCLS) are treated with angiotensin-II-receptor blockers or ACE-inhibitors to study effects on lung cells. Moreover, the CPI teamed up with the European registry LEOSS (https://leoss.net/about/) to clarify, whether there is any hint for detrimental courses of ACE inhibitor treated COVID-19 patients.
How does the host cell respond to SARS-CoV-2 infection?
So far, there is little knowledge regarding the cellular pathways activated upon SARS-CoV-2 infection. However, these cellular processes are key to understanding how the virus replicates in cells and how this could be pharmacologically perturbed. CPI researcher Christian Münch, together with the Cinatl laboratory (Virology, University Hospital Frankfurt), addressed this question. They developed a human epithelial cell infection system with viral isolate from a COVID-19 patient and studied the protein and translation changes after infection over time. They discovered several key pathways and showed that inhibition of these pathways prevents viral replication in cells (preprint: https://www.researchsquare.com/article/rs-17218/v1). This opens up several new avenues of therapeutic strategies to target COVID-19.
CPI joined “Frankfurt Debate”
The “Frankfurt interdisciplinary debate” is an attempt at dialogue between representatives of different scientific disciplines on current issues – currently (and certainly for a while) in the context of the corona crisis.
To visit the “Frankfurt Debate” website click here…
CPI sites joined LEOSS
The Lean European Open Survey on SARS-CoV-2 Infected Patients studies SARD-CoV-2 collectively.
Why: To gather information on the best possible clinical management of patients as well as prediction and prevention of severe outcomes
How: LEOSS establishes a quick and simple register that allows anonymous documentation of patients. This data can be used to identify independent predictors of outcome in patients with diagnosed infection by SARS-CoV-2.
How does COVID-19 crisis affect CPI members
Prof. Dr. Dr. Thomas Braun, coordinator CPI
How does the COVID-19 pandemia affect basic science research?
COVID-19 has turned our research upside down. We try to cope as best as we can with the situation but regular routines have been disrupted and most colleagues work in home office. On the other hand, this unusual and challenging situation offers new opportunities, allowing us to finish manuscripts and think about innovative projects and concepts. Despite the current limitations, we have intensified our research on lung regeneration. which seems more important than ever to cope with the devastating effects of viral infections of the lung.
Dr. Guillermo Luxan, postdoc
How does COVID-19 affects science and society in Spain as compared to Germany?
My family and friends live in Madrid that has become into one of the main centers of COVID-19 in Spain, and in Europe. This pandemic affects everything in Spain, from human relationships to science, of course, as all the efforts are devoted to stop the spread of the virus. My parents, my grandmother, my friends and colleagues have not abandoned their flats in the last two weeks, and now the government has ordered two more weeks of confinement with even more strict restrictions. The country has been brought to a stop and this also means its science. Research Institutes are closed, and yes, data can be analyzed from home and papers and thesis can be written from home but the laboratories are not producing any new data and at some point, the whole research effort in Spain will also come to a complete stop.
The differences with Germany are enormous. Although our lives have been affected by the spread of the disease, it can’t be compared at any level with Spain, or Italy. Here, live goes on. I see, in one hand, responsibility regarding social distancing. We, in the lab, have reduced the our presence to a minimum. We take shifts in the labs to reduce amount of people at the same time in one room and all our meetings are gone online. But on the other hand, it is not uncommon to see people gathering in the river and in the parks in the evening.
I really hope that all the measures and preparations that Germany has undergone expecting this ticking bomb to explode are enough and that we don’t need to stop our lives like my family and friends in Madrid. I also hope, that once this is over, Germany and the other EU countries help Spain, and Italy, to recover from the economic crisis that will come after the clinical crisis because there is going to be a lot of help needed.
Dr. Nuno Guimarães Camboa, junior research group leader
How does it feel to start living in a shut down country and how does the situation affect your scientific work?
CPI in (online) newspapers and TV about the current Corona Virus Outbreak:
Dr. István Vadász, Gießener Anzeiger, UKGM Gießen: Mehr Corona-Intensiv-Patienten als bei erster Welle, 16.11.2020
Prof. Susanne Herold, ARD Extra Halbzeit Bilanz der Anfang November verschärften Corona-Maßnahmen, 16.11.2020
Prof. Susanne Herold, FAZ “Gerade wurde der letzte Patient aus der ersten Welle entlassen”, 13.11.2020
Prof. Stefanie Dimmeler, FAZ “Coronavirus kann im Labor Herzzellen infizieren” 13.11.2020
Prof. Andreas Zeiher, Tagesspiegel, Mediziner warnen vor COVID-19-Folgen für Herzpatienten, 12.11.2020
Prof. Werner Seeger, Wetterauer Zeitung “Es hilft nichts, Betten in Hallen zu stellen”, 10.11.2020
Prof. Ardeschir Ghofrani, Wetterauer Zeitung, Corona in der Wetterau: “Notfall-Szenario” in Bad Nauheimer Kerckhoff-Klinik absehbar, 29.10.2020
Prof. Susanne Herold, Gießener Allgemeine, 24.10.2020
Prof. Susanne Herold bei Maybrit Illner, ZDF 22.10.2020
Prof. Susanne Herold im ARD Extra zur Herbststrategie gegen Corona, 08.10.2020
Prof. Ardeschir Ghofrani, Wetterauer Zeitung, Corona: Arzt über Langzeitfolgen für den Körper, 24.08.2020
Prof. Ardeschir Ghofrani, Giessener Allgemeine, Corona und die Langzeitfolgen, 23.08.2020
Protein gegen Covid-19: Gießener Forscher testen Wirkstoff, RTL, 21.08.2020
Prof. Susanne Herold in der Tagesschau, 13.08.2020
Prof. Ivan Dikic, FAZ, Mit “Doppelschlag” gegen Corona, 29.07.2020
Prof. Andreas Zeiher, Focus, Gefahr Bluthochdruck: Herz-Professor erklärt, für wen das ein Corona-Risiko ist, 24.07.2020
Dr. István Vadász, Gießener Anzeiger, Corona-Patient bis zu 8 Wochen auf Intensivstation, 30.05.2020
Prof. Andreas Zeiher, Die Welt, Mehr Herzkranke und Krebstote durch Corona?, 16.05.2020
Dr. Christian Münch, MDR, Frankfurter Forscher finden neue Wirkstoffe gegen das Coronavirus, 14.05.2020
Prof. Werner Seeger in Gießener Allgemeine – Überraschend ist, dass das Lungenversagen sich so lange hinzieht
Prof. Werner Seeger in ARD Extra in the UKGM, minute 7:30, 30.04.2020
Prof. Werner Seeger in Hessenschau, 30.04.2020
Prof. Susanne Herold in Hart aber fair, 27.04.2020
Prof. Christos Samakovlisi, DZL press release Wie SARS-CoV-2 in den Körper gelangt, original publication in naturemedicine: https://www.nature.com/articles/s41591-020-0868-6, human cell atlas: https://www.humancellatlas.org/, 23.04.2020
Prof. Susanne Herold cited in the New York Times “A German Exception? Why is the Country´s Coronavirus Death Rate is Low”, 04.04.2020
Prof. Susanne Herold in hartaberfair-extra: Das Virus befällt die Wirtschaft: Wieviel bleibt von unserem Wohlstand?, 30.03.2020
Prof. Susanne Herold with the Minister of Health Jens Spahn and RKI-President Prof. Lothar Wieler in a press conference, 26.03.2020
Prof. Susanne Herold in an Interview in Steingarts Morgenbriefing, 23.03.2020
Prof. Susanne Herold in maischberger. die Woche, 18.03.2020
Prof. Susanne Herold in the BMBF Press Conference “Corona-Krise: „Achtsamkeit ja, Alarmismus nein“, 11.03.2020
Prof. Susanne Herold in an interview “Gießener Allgemeine – Kampf dem Lungenversagen“, 09.03.2020
BMBF-Interview with Prof. Susanne Herold “Welche Therapien gegen das Virus gibt es?”, 09.03.2020
Prof. Susanne Herold in an interview at h+ live, 25.02.2020
Prof. Susanne Herold in an interview with Garbor Steingart about SARS-CoV-2, 29.01.2020
Prof. Susanne Herold gave an interview for the Abendzeitung ,30.01.2020
Prof. Susanne Herold in the ZDF special – Kampf gegen das Coronavirus, 05.02.2020.